4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60,950,145 | -29.6% | 4,787,914 | 0.0% | 0.25% | -30.2% |
| Q2 2023 | $86,517,606 | +27.8% | 4,787,914 | +21.6% | 0.35% | +11.3% |
| Q1 2023 | $67,692,742 | -22.6% | 3,937,914 | 0.0% | 0.32% | -27.4% |
| Q4 2022 | $87,461,070 | +176.2% | 3,937,914 | 0.0% | 0.44% | +200.0% |
| Q3 2022 | $31,661,000 | +15.2% | 3,937,914 | 0.0% | 0.15% | +15.9% |
| Q2 2022 | $27,487,000 | -53.8% | 3,937,914 | 0.0% | 0.13% | -47.7% |
| Q1 2022 | $59,541,000 | -31.1% | 3,937,914 | 0.0% | 0.24% | -3.2% |
| Q4 2021 | $86,398,000 | -18.7% | 3,937,914 | 0.0% | 0.25% | -14.4% |
| Q3 2021 | $106,206,000 | +12.0% | 3,937,914 | 0.0% | 0.29% | +1.0% |
| Q2 2021 | $94,825,000 | -44.5% | 3,937,914 | 0.0% | 0.29% | -43.4% |
| Q1 2021 | $170,827,000 | +4.7% | 3,937,914 | 0.0% | 0.51% | +13.4% |
| Q4 2020 | $163,227,000 | – | 3,937,914 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |